Vivere Oncotherapies

Unmask Cold Tumors

Berkeley, California, US

Vivere Oncotherapies is a bioengineering company developing targeted gene therapies to activate the immune system against "cold" solid tumors that are resistant to existing treatments.

Shareable draft

Check out Vivere Oncotherapies on @MedStartr Today Vivere Oncotherapies is a bioengineering company developing targeted gene therapies to activate the immune system against "cold" solid tumors that are resistant to existing treatments. #CancerOncology #DrugDiscoveryDevelopment #MedMo #MedStartrVentures

https://www.medstartr.ai/s/Tb8Y-29NYuU

Get Involved in Vivere Oncotherapies

Problem Statement

"Cold" solid tumors, such as colorectal and ovarian cancers, evade immune detection and are resistant to existing immunotherapies like checkpoint inhibitors, creating a lack of effective treatment options.

Core Technology

Proprietary bioengineering platform using gene therapy, viral vector engineering, and immuno-oncology to create targeted therapies for solid tumors.

Key Differentiators

Engineered delivery vehicles capable of selective tumor replication; Multi-antigen immune cell targeting; Expression of therapeutic cargoes to address immunosuppressive tumor environments; Use of directed evolution to create highly specific vectors and genetic cargoes

Clinical Focus

Oncology

Company Info

Business Model: Service
Total Funding: Only accessible to MedStartr community members. Join now
Only accessible to MedStartr community members.
Join now
Website: www.viveretx.com

Disease Areas

Cancer & Oncology

Technologies

BioengineeringGene TherapyViral VectorsImmuno-OncologyDirected Evolution

Clinical & IP

🔬

Clinical Validation

Preclinical validation in colorectal cancer models showing improved tumor distribution, size reduction, and survival. Platform-stage technology targeting solid tumor indications.

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of Vivere Oncotherapies?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.